ANDA 90367, held by Chartwell Rx. Levofloxacin.
As of Nov 16, 2026, ANDA 90367 (Levofloxacin), held by Chartwell Rx, was first approved by FDA on Jun 20, 2011, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2011 | Original application | Approved | None posted |
| Levofloxacin250MG · tablet;oral | Levofloxacin | Discontinued |
| Levofloxacin500MG · tablet;oral | Levofloxacin | Discontinued |
| Levofloxacin750MG · tablet;oral | Levofloxacin | Discontinued |
| Feb 11, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 19, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 24, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 12, 2012 | Supplement 1Labeling | Approved | None posted |
| Jun 20, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters